These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31094083)

  • 21. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
    Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of sarcopenia in older patients with colorectal cancer.
    Broughman JR; Williams GR; Deal AM; Yu H; Nyrop KA; Alston SM; Gordon BB; Sanoff HK; Muss HB
    J Geriatr Oncol; 2015 Nov; 6(6):442-5. PubMed ID: 26365898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction.
    Baird R; Biondo A; Chhaya V; McLachlan J; Karpathakis A; Rahman S; Barbachano Y; Cunningham D; Chau I
    Br J Cancer; 2011 Jan; 104(1):43-50. PubMed ID: 21063416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
    Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R
    BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
    Schmiegel W; Reinacher-Schick A; Arnold D; Kubicka S; Freier W; Dietrich G; Geißler M; Hegewisch-Becker S; Tannapfel A; Pohl M; Hinke A; Schmoll HJ; Graeven U
    Ann Oncol; 2013 Jun; 24(6):1580-7. PubMed ID: 23463625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib.
    Gökyer A; Küçükarda A; Köstek O; Hacıoğlu MB; Sunal BS; Demircan NC; Uzunoğlu S; Solak S; İşsever K; Çiçin I; Erdoğan B
    Clin Transl Oncol; 2019 Nov; 21(11):1518-1523. PubMed ID: 30868388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of sarcopenia with severe chemotherapy toxicities and survival in patients with advanced gastric cancer.
    Chan WL; Yun HB; Cheung EE; Liu M; Hou LY; Lam KO; Wong IY; Chiu WK; Law S; Kwong D
    Oncologist; 2024 Oct; 29(10):e1272-e1279. PubMed ID: 38885304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.
    Huillard O; Mir O; Peyromaure M; Tlemsani C; Giroux J; Boudou-Rouquette P; Ropert S; Delongchamps NB; Zerbib M; Goldwasser F
    Br J Cancer; 2013 Mar; 108(5):1034-41. PubMed ID: 23462722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
    Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
    Venderbosch S; Doornebal J; Teerenstra S; Lemmens W; Punt CJ; Koopman M
    Acta Oncol; 2012 Sep; 51(7):831-9. PubMed ID: 22794910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
    Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner SH; Brennscheidt U; Feyereislova A; Delord JP
    Ann Oncol; 2008 Feb; 19(2):332-9. PubMed ID: 17986625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer.
    Lee J; Lin JB; Wu MH; Jan YT; Chang CL; Huang CY; Sun FJ; Chen YJ
    J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):814-826. PubMed ID: 31094101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer.
    Park SE; Choi JH; Park JY; Kim BJ; Kim JG; Kim JW; Park JM; Chi KC; Hwang IG
    Sci Rep; 2020 Oct; 10(1):17683. PubMed ID: 33077864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial).
    Kosugi C; Koda K; Denda T; Ishibashi K; Ishida H; Seike K; Sakata H; Yanagisawa S; Miyazaki A; Takayama W; Koike N; Shimizu H; Matsubara H
    Int J Colorectal Dis; 2021 Dec; 36(12):2637-2647. PubMed ID: 34368890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: A randomized controlled trial.
    van der Werf A; Langius JAE; Beeker A; Ten Tije AJ; Vulink AJ; Haringhuizen A; Berkhof J; van der Vliet HJ; Verheul HMW; de van der Schueren MAE
    Clin Nutr; 2020 Oct; 39(10):3005-3013. PubMed ID: 32037284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study.
    da Rocha IMG; Marcadenti A; de Medeiros GOC; Bezerra RA; Rego JFM; Gonzalez MC; Fayh APT
    J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):445-454. PubMed ID: 30924270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study.
    Maddalena C; Ponsiglione A; Camera L; Santarpia L; Pasanisi F; Bruzzese D; Panico C; Fiore G; Camardella S; Caramia T; Farinaro A; De Placido S; Carlomagno C
    World J Clin Oncol; 2021 May; 12(5):355-366. PubMed ID: 34131567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer.
    Loree JM; Sha A; Soleimani M; Kennecke HF; Ho MY; Cheung WY; Mulder KE; Abadi S; Spratlin JL; Gill S
    Clin Colorectal Cancer; 2018 Jun; 17(2):156-163. PubMed ID: 29486916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.